Analyst Price Target is $6.33
▲ +339.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for DermTech in the last 3 months. The average price target is $6.33, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 339.81% upside from the last price of $1.44.
Current Consensus is
The current consensus among 4 contributing investment analysts is to moderate buy stock in DermTech. This Moderate Buy consensus rating has held steady for over two years.
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.